Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays

doi:10.1128/JCM.00779-19

Comment

. 2019 Aug 26;57(9):e00779-19.

doi: 10.1128/JCM.00779-19. Print 2019 Sep.

Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays

Patrick Murray¹, Charles Cooper², Courtney Maus³

Affiliations

¹ Scientific Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA Patrick_murray@BD.com.
² Medical Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA.
³ Scientific Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA.

PMID: 31451572
PMCID: PMC6711926
DOI: 10.1128/JCM.00779-19

Comment

Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays

Patrick Murray et al. J Clin Microbiol. 2019.

. 2019 Aug 26;57(9):e00779-19.

doi: 10.1128/JCM.00779-19. Print 2019 Sep.

Authors

Patrick Murray¹, Charles Cooper², Courtney Maus³

Affiliations

¹ Scientific Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA Patrick_murray@BD.com.
² Medical Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA.
³ Scientific Affairs, BD Life Sciences, Franklin Lakes, New Jersey, USA.

PMID: 31451572
PMCID: PMC6711926
DOI: 10.1128/JCM.00779-19

No abstract available

Keywords: BD MAX MDR TB; INH resistance.

PubMed Disclaimer

Comment in

Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".
Mokaddas EM, Ahmad S, Eldeen HS. Mokaddas EM, et al. J Clin Microbiol. 2019 Aug 26;57(9):e00984-19. doi: 10.1128/JCM.00984-19. Print 2019 Sep. J Clin Microbiol. 2019. PMID: 31451575 Free PMC article. No abstract available.

Comment on

GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).
Mokaddas EM, Ahmad S, Eldeen HS. Mokaddas EM, et al. J Clin Microbiol. 2019 May 24;57(6):e00537-19. doi: 10.1128/JCM.00537-19. Print 2019 Jun. J Clin Microbiol. 2019. PMID: 30971464 Free PMC article. No abstract available.

Cited by

The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates.
David A, Singh L, Da Silva P, Scott L, Stevens W. David A, et al. Infect Drug Resist. 2020 Sep 28;13:3301-3308. doi: 10.2147/IDR.S247524. eCollection 2020. Infect Drug Resist. 2020. PMID: 33061477 Free PMC article.
Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".
Mokaddas EM, Ahmad S, Eldeen HS. Mokaddas EM, et al. J Clin Microbiol. 2019 Aug 26;57(9):e00984-19. doi: 10.1128/JCM.00984-19. Print 2019 Sep. J Clin Microbiol. 2019. PMID: 31451575 Free PMC article. No abstract available.
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay S, Steingart KR, Davies GR, Chaplin M, De Vos M, Schumacher SG, Warren R, Theron G. Pillay S, et al. Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2. Cochrane Database Syst Rev. 2022. PMID: 35583175 Free PMC article.

References

1. Mokaddas EM, Ahmad S, Eldeen HS. 2019. GeneXpert MTB/RIF is superior to BD MAX MDR-TB for diagnosis of TB in a country with low incidence of MDR-TB. J Clin Microbiol 57:e00537-19. doi:10.1128/JCM.00537-19. - DOI - PMC - PubMed
1. Mokaddas E, Ahmad S, Samir I. 2008. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996–2005. Int J Tuberc Lung Dis 12:319–325. - PubMed
1. Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. 2019. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis 19:3. doi:10.1186/s12879-018-3638-z. - DOI - PMC - PubMed
1. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. 2017. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 17:223–234. doi:10.1016/S1473-3099(16)30407-8. - DOI - PubMed
1. Romanowski K, Campbell JR, Oxlade O, Fregonese F, Menzies D, Johnston JC. 2019. The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: a modelling study. PLoS One 14:e0211355. doi:10.1371/journal.pone.0211355. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Mokaddas EM, Ahmad S, Eldeen HS. 2019. GeneXpert MTB/RIF is superior to BD MAX MDR-TB for diagnosis of TB in a country with low incidence of MDR-TB. J Clin Microbiol 57:e00537-19. doi:10.1128/JCM.00537-19. - DOI - PMC - PubMed

[2] Mokaddas EM, Ahmad S, Eldeen HS. 2019. GeneXpert MTB/RIF is superior to BD MAX MDR-TB for diagnosis of TB in a country with low incidence of MDR-TB. J Clin Microbiol 57:e00537-19. doi:10.1128/JCM.00537-19. - DOI - PMC - PubMed

[3] Mokaddas E, Ahmad S, Samir I. 2008. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996–2005. Int J Tuberc Lung Dis 12:319–325. - PubMed

[4] Mokaddas E, Ahmad S, Samir I. 2008. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996–2005. Int J Tuberc Lung Dis 12:319–325. - PubMed

[5] Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. 2019. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis 19:3. doi:10.1186/s12879-018-3638-z. - DOI - PMC - PubMed

[6] Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. 2019. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis 19:3. doi:10.1186/s12879-018-3638-z. - DOI - PMC - PubMed

[7] Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. 2017. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 17:223–234. doi:10.1016/S1473-3099(16)30407-8. - DOI - PubMed

[8] Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. 2017. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 17:223–234. doi:10.1016/S1473-3099(16)30407-8. - DOI - PubMed

[9] Romanowski K, Campbell JR, Oxlade O, Fregonese F, Menzies D, Johnston JC. 2019. The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: a modelling study. PLoS One 14:e0211355. doi:10.1371/journal.pone.0211355. - DOI - PMC - PubMed

[10] Romanowski K, Campbell JR, Oxlade O, Fregonese F, Menzies D, Johnston JC. 2019. The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: a modelling study. PLoS One 14:e0211355. doi:10.1371/journal.pone.0211355. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays

Affiliations

Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays

Authors

Affiliations

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical